Login to apply

Despite the availability of drug treatment regimens, tuberculosis remains a major global health concern, with an estimated 8.2 million new cases reported in 2023, including 400,000 cases of drug-resis...

LSTM Research Centre Showcase 2025 – Learn 2 and 3, Pembroke House, Tue 23 Sep 2025 - On 23rd September in Pembroke House, the Centre for Drugs and Diagnostics (CDD) will host its annual showcase even...

Dr Jeremy Burrows, Professor Tanya Parish, and Dr Ami Patel will bring unique expertise in medicinal chemistry, drug discovery, vaccinology and antibody-based therapeutics into LSTM, enhancing its

In many competitive industries, sponsorship is often seen as a key driver of career advancement. A new study from UC San Diego’s Rady School of Management reveals that men and women take distinctly di...

MmpL3 is a promising new target for antitubercular drugs, but the microbiological properties of MmpL3 inhibitors are not fully understood. We compared the activity and mode of action of 11 structurall...

We previously identified a morpholinobenzamide series with potent activity against Mycobacterium tuberculosis. We conducted structure–activity relationship studies focusing on removing the metabolically labile morpholine group while retaining antibacterial activity. We identified potent benzamides 16 (IC90 = 0.13 μM) and 22f (IC90 = 0.09 μM) with a thiophene and methyl substituents replacing the morpholine at the C-5 position. These analogs had high selectivity (selectivity index = 300 and 278, respectively) and low cytotoxicity (HepG2 CC50 of 39 and 25 μM, respectively). Compound 16 demonstrated a good metabolic stability in human liver microsomes.

YouTube video by American Society for Microbiology